INIS
patients
100%
tyrosine
62%
kinases
62%
reviews
51%
blood cells
39%
myeloid leukemia
35%
applications
32%
risks
32%
comparative evaluations
29%
thrombin
28%
plasma
26%
production
22%
phospholipids
21%
dimers
19%
atherosclerosis
19%
in vitro
19%
thrombosis
18%
biological markers
17%
reagents
15%
anticoagulants
15%
lymphomas
15%
neutrophils
15%
ruptures
15%
storage
15%
emergencies
15%
matrices
15%
data
15%
complement
11%
diseases
10%
sensitivity
9%
transfusions
8%
migration
8%
concentration
8%
origin
7%
hemolysis
7%
death
7%
levels
7%
viability
7%
macrophages
6%
boron 19
6%
variations
6%
doses
6%
morphology
6%
adhesion
6%
molecules
6%
apoptosis
5%
control
5%
blood
5%
Medicine and Dentistry
Procoagulant
31%
Thrombosis
31%
Tyrosine-Kinase Inhibitor
31%
Endothelial Cell
18%
Dasatinib
18%
Biological Marker
18%
Acute Leukemia
18%
Chronic Myelogenous Leukemia
17%
Venous Thromboembolism
17%
Erythrocyte Concentrate
15%
In Vitro
15%
microRNA
15%
Disseminated Intravascular Coagulation
15%
Edoxaban
15%
Acute Myeloid Leukemia
15%
Leukemia Cell
15%
Multidrug Resistance
15%
Paroxysmal Nocturnal Hemoglobinuria
15%
HL60
15%
Cell Survival
15%
Cell Function
15%
D-Dimer
15%
Myelodysplastic Syndrome
15%
Hemophagocytosis
15%
Neutrophil
15%
Meta-Analysis
15%
Systematic Review
15%
Emergency Department
15%
Drug Resistance
13%
Imatinib
12%
Ponatinib
11%
Thrombin
11%
Nilotinib
10%
Morphology
9%
Erythrocyte
7%
Multidrug Resistance Protein 1
7%
Independent Reviewer
7%
Cell Adhesion Molecule
5%
Cancer Cell
5%
Phospholipid
5%
Keyphrases
Major Molecular Response
15%
Chronic Myeloid Leukemia
15%
BCR-ABL Inhibitors
15%
Del(20q)
15%
Myelodysplasia
15%
Erythrophagocytosis
15%
Longitudinal Clinical Study
15%
Prospective Longitudinal Study
15%
Acute Myeloid Leukemia Cells
15%
Red Cell Concentrates
15%
Direct Oral Anticoagulants
15%
Neutrophils
15%
Atherosclerosis Plaque
15%
Plaque Rupture
15%
Edoxaban
15%
Age-adjusted Cutoff
15%
D-dimer
15%
Emergency Department
15%
Leukemia Patients
15%
Arterial Events
11%
Vascular Occlusive Events
11%
Myelodysplastic Syndrome
9%
Platelet-free Plasma
8%
Ponatinib
6%
Nilotinib
6%
Vesicle Production
6%
Morphological Characteristics
6%
Cytogenetic Abnormalities
6%
Fibrous Cap
5%